|
Peripheral Arterial Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Although many PAD biomarkers are indicative of PAD in both males and females, some are strongly correlated with the disease in females.
|
29750230 |
2019 |
|
Peripheral Arterial Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Background The effects of race on response to medical therapy in people with peripheral artery disease ( PAD ) are unknown.
|
30661439 |
2019 |
|
Peripheral Arterial Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Indications for the revascularization treatment of peripheral arterial disease (PAD) generate much discussion, and practice varies significantly among hospitals.
|
30860341 |
2019 |
|
Peripheral Arterial Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Background Prevalence of peripheral artery disease ( PAD ) is significantly higher among blacks as compared with non-Hispanic whites, but the role of cigarette smoking in PAD is understudied in blacks.
|
30672360 |
2019 |
|
Peripheral Arterial Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Background With advances in peripheral artery disease ( PAD ) treatments such as endovascular treatment ( EVT ), personalized patient assessment is important.
|
30663486 |
2019 |
|
Peripheral Arterial Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Methods and Results A total of 1272 patients with PAD and new or worsening claudication were enrolled at 16 vascular specialty clinics (2011-2015, PORTRAIT (Patient-Centered Outcomes Related to Treatment Practices in Peripheral Arterial Disease: Investigating Trajectories) registry).
|
30371269 |
2018 |
|
Peripheral Arterial Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Peripheral artery disease ( PAD ) is a manifestation of systematic atherosclerosis.
|
30486720 |
2018 |
|
Peripheral Arterial Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Background Poor lower extremity physical performance is an independent predictor of unfavorable outcome in patients with peripheral artery disease ( PAD ); however, few studies have assessed muscle characteristics on imaging directly.
|
30371256 |
2018 |
|
Peripheral Arterial Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Dominant hand grip strength was measured during ambulatory clinic visits among patients with vascular disease (abdominal aortic aneurysm [AAA], carotid stenosis, and peripheral artery disease [PAD]).
|
29276105 |
2018 |
|
Peripheral Arterial Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The treatment arm of the randomized, double-blind, multicenter MarrowStim PAD Kit for the Treatment of Critical Limb Ischemia in Subjects with Severe Peripheral Arterial Disease (MOBILE) trial was stratified by ethnicity and evaluated for demographics, comorbidities, and outcomes.
|
29503004 |
2018 |
|
Peripheral Arterial Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Background We conducted an analysis of data from the ARIC (Atherosclerosis Risk in Communities) study to assess the independent association of obesity with peripheral artery disease ( PAD ) and critical limb ischemia ( CLI ).
|
30369315 |
2018 |
|
Peripheral Arterial Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
A1c = hemoglobin A1c; ABC = hemoglobin A1c, blood pressure, low-density-lipoprotein cholesterol; ACE = angiotensin-converting enzyme; ADA = American Diabetes Association; ARB = angiotensin receptor blocker; BMI = body mass index; BP = blood pressure; CHD = coronary heart disease; CVD = cardiovascular disease; HCHS/SOL = Hispanic Community Health Study/Study of Latinos; LDL-C = low-density-lipoprotein cholesterol; NHANES = National Health and Nutrition Examination Survey; PAD = peripheral artery disease.
|
28816530 |
2017 |
|
Peripheral Arterial Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Therefore, we describe and rationalize the MarrowStim PAD Kit for the Treatment of Critical Limb Ischemia in Subjects with Severe Peripheral Arterial Disease (MOBILE) trial, a study geared to provide the pivotal proof of efficacy of cBMA in CLI.
|
28390770 |
2017 |
|
Peripheral Arterial Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
We use the Hill function to analyze the dynamics of Tc-99m 2 methoxy-isobutyl-isonitrile (Tc-MIBI) scintigraphy data and to examine the earlier lower extremity microvascular perfusion of diabetic patients without typical clinical symptoms and with the preserved normal ankle-brachial index (ABI).Eighty-eight participants (30 healthy control, 34 diabetic patients, and 24 diabetic patients with peripheral arterial disease [PAD]) were recruited and applied Tc-MIBI scintigraphy.
|
28930839 |
2017 |
|
Peripheral Arterial Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
ACEI = angiotensin-converting enzyme inhibitors; ADA = American Diabetes Association; ARB = angiotensin-receptor blocker; CAD = coronary artery disease; Cr = creatinine; CVD = cardiovascular disease; DM = diabetes mellitus; HF = heart failure; HT = hypertension; JNC = Joint National Committee; KAUH = King Abdullah University Hospital; LV = left ventricular; PAD = peripheral artery disease; RAAS = renin-angiotensin-aldosterone system; TIA = transient ischemic attack.
|
28816537 |
2017 |
|
Peripheral Arterial Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The EUCLID trial (Examining Use of Ticagrelor In PAD) randomized 13 885 patients with peripheral artery disease to treatment with ticagrelor 90 mg twice daily or clopidogrel 75 mg daily.
|
27840336 |
2017 |
|
Peripheral Arterial Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Relationships between LJM of the hand and foot risk according to IWGDF category, HbA1c, age, body mass index, blood pressure, estimated glomerular filtration (eGFR), and diabetic complications (including diabetic peripheral neuropathy [DPN] and peripheral arterial disease [PAD]) were evaluated in 528 consecutive T2D patients.
|
27531043 |
2017 |
|
Peripheral Arterial Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Peripheral artery disease (PAD) generates tissue ischemia through arterial occlusions and insufficient collateral vessel formation.
|
25362254 |
2014 |
|
Peripheral Arterial Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Overall, the association between these genetic disorders and the three main arterial complications (myocardial infarction [MI], ischemic stroke [IS], and peripheral arterial disease [PAD]) is modest.
|
17433903 |
2007 |